At a glance
ClinicalIndex Comparison Record- ✓Moderate to severe anemia
- ✓Iron deficiency
- ✓Moderate to severe chronic kidney disease
- ✕Currently receiving dialysis
- ✕Known sensitivity to Ferrlecit® or any of its components
- ✕Currently receiving erythropoietic agent therapy
- ✕Clinically unstable
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease
In Brief
A Phase 4 clinical trial evaluating Sodium Ferric Gluconate Complex in Sucrose Injection and Ferrous sulfate tablets for Anemia, Iron-Deficiency and Kidney Failure, Chronic. Completed, enrolled 89 participants across 24 sites in 2 countries.
Detailed Summary
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cells).
Study Details
Timeline
Interventions
Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
ferrous sulfate, 325 mg oral, three times daily for 6 weeks